Apheris
PrivateLast Round
Series A
Jan 2, 2025
Total Funding Raised
$17.83M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Apheris is a software company that provides a federated computing platform enabling secure, private, and governed access to distributed data for machine learning and analytics, primarily in the life sciences sector.
Sector
AI, Data & Cloud Infrastructure
Verticals
Drug Discovery, Data Governance, ML Platforms, Data Protection
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apheris Comparables
Compare Apheris with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rhino Health, Inc. | 88% | |
| Lifebit | 84% | |
| integrate.ai | 81% |
Apheris Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 2, 2025 | ||||
| Seed | Nov 8, 2022 | ||||
| Grant | Aug 20, 2020 |
Apheris Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| System.One | Grant |
| Dig Ventures | Grant, Seed |
| OTB Ventures | Series A |
| System.One | Grant |
| eCapital | Series A |
| Phoenix Court Group | Seed, Grant |
| LocalGlobe | Seed, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 19, 2026
Grew 19% QoQ, from 54 to 64 employees.
- Aug 15, 2026
Grew 15% QoQ, from 52 to 60 employees.
Recent news
Latest coverage and updates
- partners_withOct 21, 2026
Apheris AI GmbH and T-Systems partner to enable European customers to run federated clinical and drug-discovery research networks on sovereign cloud infrastructure, keeping patient data in originating hospitals while combining privacy-compliant model parameters on Germany-operated Industrial AI Cloud, with the collaboration presented in Germany on Oct 21st '26.
- partners_withSep 29, 2026
Apheris GmbH partners with Ginkgo Bioworks, Inc. through the Antibody Developability Consortium to pool privacy-preserving proprietary data and train AI on 10,000 antibodies, with the consortium kicking off in Germany on Sep 29th '26.
Apheris Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Apheris's valuation, stock price, and market status.
Is Apheris a public or private company?
Apheris is a private company.
What is the current stock price of Apheris?
Apheris is a private company, so its shares have no public market price. Caplight tracks Apheris's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Apheris worth (valuation)?
Valuation information for Apheris is not publicly available.
Can I buy Apheris stock?
Apheris shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Apheris's last funding round?
Apheris's most recent funding round was Series A on January 2, 2025.
Who are the main investors in Apheris?
Key investors in Apheris include OTB Ventures, eCapital, Phoenix Court Group, LocalGlobe, Octopus Ventures.
Will Apheris IPO soon?
No public IPO plans have been announced for Apheris.
How can I track Apheris secondary market activity?
Caplight tracks bids, offers, and trades in Apheris's shares on secondary markets.